Skip to main content

Celgene CEO: New therapies for a certain type of cancer boost survival rates 10-fold

Celgene and Bluebird Bio find results in treating patients with multiple myeloma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.